These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 30347480)

  • 21. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
    Cousin S; Italiano A
    Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
    Hsu JC; Lin JY; Hsu MY; Lin PC
    PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia.
    Rattarittamrong E; Eiamprapai P; Tantiworawit A; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Norasetthada L
    Hematology; 2016 Jul; 21(6):368-74. PubMed ID: 27077773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects.
    Dalvin LA; Shields CL; Orloff M; Sato T; Shields JA
    Retina; 2018 Jun; 38(6):1063-1078. PubMed ID: 29689030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of scleroderma according to the type of immune checkpoint inhibitors.
    Terrier B; Humbert S; Preta LH; Delage L; Razanamahery J; Laurent-Roussel S; Mestiri R; Beaudeau L; Legendre P; Goupil F; Hadjadj J; Stolzenberg MC; Treluyer JM; Westeel V; Valnet-Rabier MB; Wislez M; Mouthon L; Chouchana L
    Autoimmun Rev; 2020 Aug; 19(8):102596. PubMed ID: 32540450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report.
    Ogawa K; Ito J; Fujimoto D; Morita M; Yoshizumi Y; Ariyoshi K; Tomii K; Katakami N
    Invest New Drugs; 2018 Jun; 36(3):509-512. PubMed ID: 29340837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal effects of immune checkpoint inhibitors.
    Izzedine H; Mateus C; Boutros C; Robert C; Rouvier P; Amoura Z; Mathian A
    Nephrol Dial Transplant; 2017 Jun; 32(6):936-942. PubMed ID: 28025384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.
    Ariyasu H; Inaba H; Ota T; Yamaoka H; Furukawa Y; Iwakura H; Doi N; Yamamoto Y; Akamizu T
    In Vivo; 2018; 32(2):345-351. PubMed ID: 29475919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.
    Reynaud Q; Durieu I; Dutertre M; Ledochowski S; Durupt S; Michallet AS; Vital-Durand D; Lega JC
    Autoimmun Rev; 2015 Apr; 14(4):304-13. PubMed ID: 25497766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
    Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
    Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenging Cases: Management of Immune-Related Toxicity.
    Weber JS
    Am Soc Clin Oncol Educ Book; 2018 May; 38():179-183. PubMed ID: 30231403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis.
    Larsen BT; Chae JM; Dixit AS; Hartman TE; Peikert T; Roden AC
    Am J Surg Pathol; 2019 Oct; 43(10):1331-1340. PubMed ID: 31162288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
    Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
    Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database.
    Garon-Czmil J; Petitpain N; Rouby F; Sassier M; Babai S; Yelehe-Okouma M; Weryha G; Klein M; Gillet P
    Fundam Clin Pharmacol; 2019 Apr; 33(2):241-249. PubMed ID: 30308083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoimmune hemolytic anemia in patients with liver transplants for primary biliary cirrhosis: Three case reports and a review of the literature.
    Retana AK; Kaplan MM; Erban JK
    Am J Gastroenterol; 2007 Jan; 102(1):197-200. PubMed ID: 17037996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
    Chism DD
    J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Sandigursky S; Mor A
    Curr Rheumatol Rep; 2018 Sep; 20(10):65. PubMed ID: 30191417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures.
    Barcellini W; Giannotta J; Fattizzo B
    Expert Rev Hematol; 2020 Jun; 13(6):585-597. PubMed ID: 32274943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Aquired immune hemolytic anemias].
    Salama A
    Ther Umsch; 2004 Feb; 61(2):178-86. PubMed ID: 15018403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.